Gain Therapeutics, Inc.
GANX
$1.71
-$0.04-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -38.17% | -10.04% | -7.59% | 9.94% | 1,701.43% |
| Gross Profit | 38.17% | 10.04% | 7.59% | -9.94% | -1,701.43% |
| SG&A Expenses | -37.28% | 12.70% | 3.58% | -27.02% | 1.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.76% | -0.13% | -24.37% | -8.72% | 5.87% |
| Operating Income | 37.76% | 0.13% | 24.37% | 8.72% | -5.87% |
| Income Before Tax | 30.39% | -10.90% | 30.70% | 4.73% | -6.27% |
| Income Tax Expenses | 11,666.67% | 405.03% | 3,380.69% | -48.84% | -95.49% |
| Earnings from Continuing Operations | 28.66% | -12.85% | 20.23% | 4.93% | -5.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.66% | -12.85% | 20.23% | 4.93% | -5.92% |
| EBIT | 37.76% | 0.13% | 24.37% | 8.72% | -5.87% |
| EBITDA | 37.80% | 0.16% | 24.38% | 8.78% | -5.88% |
| EPS Basic | 54.81% | 29.29% | 56.76% | 54.48% | 31.71% |
| Normalized Basic EPS | 55.89% | 30.53% | 62.45% | 54.39% | 31.51% |
| EPS Diluted | 54.81% | 29.29% | 56.76% | 54.48% | 31.71% |
| Normalized Diluted EPS | 55.89% | 30.53% | 62.45% | 54.39% | 31.51% |
| Average Basic Shares Outstanding | 57.90% | 59.55% | 84.46% | 108.89% | 55.13% |
| Average Diluted Shares Outstanding | 57.90% | 59.55% | 84.46% | 108.89% | 55.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |